Palivizumab

Red

Brand Name(s):Synagis

Indication:Passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants

Respiritory syncytial virus

Rationale:1,2

Considered:Dec-07

Review Date:Jul-26

Comments:
Policy from the Department of Health and Social care extends eligibility for palivizumab in the treatment of passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants